AstraZeneca cuts about 600 U.S. sales jobs, Bloomberg reports
About 600 roles on AstraZeneca's U.S. respiratory and immunology sales teams were cut, Bloomberg reported on November 13. AstraZeneca declined to comment, so the number comes from reporting.
In this brief: 4 sections 2 min read
Bloomberg reported on November 13 that about 600 jobs were cut on AstraZeneca's U.S. respiratory and immunology commercial teams, citing people familiar with the matter. Some affected staff are expected to be reassigned within the company. AstraZeneca declined to comment.
With its third-quarter results on October 30, AstraZeneca announced a three-year program targeting about $1.5 billion in annual savings, mostly to reinvest in its pipeline of more than 180 projects, with up to $2 billion in one-off charges, according to Reuters. It gave no job or location targets.
The respiratory and immunology portfolio brought in $2.5 billion in the third quarter, 16% of revenue, per Reuters' report. CEO Pascal Soriot has said the company is on track for its 2030 goal of $80 billion in annual revenue.
AstraZeneca has not confirmed the 600 figure. No press release, SEC filing or state WARN notice tied to these cuts was found, so the number rests on Bloomberg's sources.